The only potential cure for patients with myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HCT). However, a proportion of patients who are HCT candidates do not finally get transplanted. This population-based study aimed to characterize HCT candidates were attempting to reach HCT fail and to identify causes and risk factors for failure. Data were collected from (1) the national Swedish registry, enrolling 291 transplant candidates between 2009–2018, and (2) Karolinska University Hospital, enrolling 131 transplantation candidates between 2000 and 2018. Twenty-five % (nation-wide) and 22% (Karolinska) failed to reach HCT. Reasons for failure to reach HCT were progressive and refractory disease (47%), no donor identified (22%), identification of comorbidity (18%), and infectious complications (14%). Factors associated with failure to reach HCT were IPSS-R cytogenetic risk-group very poor, mixed MDS/MPN disease, low blast count (0–4.9%), and low hemoglobin levels (≤7.9 g/dL). Transplanted patients had a longer overall survival (OS) compared to patients who failed to reach transplantation (83 months versus 14 months; p < 0.001). The survival advantage was seen for the IPSS-R risk groups intermediate, high, and very high. This study demonstrated that a high proportion of HCT-candidates fail to reach HCT and underlines the difficulties associated with bridging MDS patients to HCT.

Bone Marrow Transplantation (2022) 57:598–606; https://doi.org/10.1038/s41409-022-01582-0

INTRODUCTION

Myelodysplastic syndromes (MDS) and MDS myeloproliferative neoplasms (MDS/MPN) are myeloid malignancies originating in the hematopoietic stem cell compartment [1]. A third of the cases have the higher-risk disease at diagnosis, with a median survival of less than one year [2]. Allogeneic hematopoietic stem cell transplantation (HCT) is the only curative regimen for these patients [3, 4].

The process of getting eligible patients who have accepted the procedure for transplantation is complex with many potential reasons which might prevent HCT. First, there might not be a suitable donor for the patient, secondly, the patient might get infections or develop co-morbidities during the pre-transplantation process, and thirdly the disease might progress to a high-proliferative disease where HCT is no longer expected to be successful. Moreover, beyond the complex medical issues encountered there are also logistical challenges e.g., referral of patients from rural hospitals to transplantation centers and obtaining the donor cells within an optimal time range. These logistical challenges must be overcome for a successful pre-transplantation process.

A proportion of patients are treated with disease-modifying treatment e.g., hypomethylating therapy such as Azacytidine (Aza) or intensive chemotherapy (ICT) during the pre-transplantation process [3, 5, 6]. The rationale of using disease-modifying treatment is to induce remission or reduce the tumor load and thereby reduce the risk of relapse [7–9]. Studies have shown that patients transplanted in remission have a better outcome after HCT compared to patients who have not achieved remission [7, 10]. However, retrospective studies have not been able to demonstrate superior outcomes for patients comparing patients pre-treated with Aza or ICT with HCT upfront, although selection bias might interfere with the results [8, 11, 12].

Data reporting the proportion of patients with an indication for HCT who finally never reach transplantation is limited. In a retrospective study from a Korean transplantation center including only patients treated with Azacytidine, 13% failed to reach HCT [7]. In another retrospective study from a single transplantation center...
METHODS

Data was collected from two cohorts of patients diagnosed with MDS or MDS/MPN with an intent to perform an HCT: (1) patients included in the National Swedish quality registry for MDS (registry data) and (2) consecutive patients from the Karolinska University Hospital (patient chart data). All included patients were classified according to the 2016 WHO classification [17]. Disease risk was stratified according to the IPSS-R scoring system [18].

Cohort 1

The cohort consisted of all patients aged between 18 and 74, with a diagnosis of MDS or MDS/MPN reported to the National Swedish MDS registry between 2009 and 2018 [2]. The registry has a reported coverage rate of 98%, 87%, and 65% for the years 2009–2016, 2017, and 2018, respectively, at the time of data extraction November 2019. The European bone marrow transplantation (EBMT) registry and the patient charts were used to identify which patients subsequently were transplanted and which patients failed to reach transplantation. Except for this specific information, all data on disease characteristics at diagnosis was collected from the national registry. Data on missing values are reported. During the period 2009–2015, the treating physician reported if the patient was an HCT candidate or not, while from 2015 the possible options were extended with one alternative: “HCT might be performed”. Patients who were allocated to this alternative were excluded and thus only patients with a clearly documented intention to perform HCT were included. Ethical approval for studies on cohort 1 was obtained (2017/1855-31/2).

Cohort 2

The cohort included consecutive patients aged 18–74 diagnosed with MDS or MDS/MPN at the Karolinska University hospital where the treating hematologist identified the patient as a potential transplantation candidate as documented in the patient charts. All data were collected from patient charts. Patients were diagnosed during 2000-2018, and HCT was performed between 2004 and 2019. Included patients were characterized in detail regarding disease-related parameters, pre-HCT treatment, comorbidity, marital status, and outcome. Pre-HCT treatment was categorized into Aza, ICT, or neither Aza/ICT. Comorbidity was assessed using the hematopoietic cell transplantation-comorbidity index (HCT-CI) [19]. Causes of failure to reach HCT were categorized into four categories defined as a progressive or refractory disease, no suitable donor identified, infection (uncontrolled/life-threatening infection), and identification of comorbidity (new condition or impaired functional status after the documentation of the patient being a potential transplantation candidate) making the patient unsuitable as a transplantation candidate. Ethical approval for studies on cohort 2 was obtained (2017/1090-31/4).

Statistics

Continuous variables were expressed with the median (range). Normality was tested using the Shapiro–Wilk test. Frequency tables were used for summarizing categorical variables. Statistical methods used for association studies were the Mann–Whitney test for non-parametric distributed continuous variables and a Chi-squared test for categorical data. Binary logistic regression was used for multivariate analysis (backward conditional) of parameters associated with failure to reach HCT. Time-to-event data were analyzed using the Kaplan–Meier method. OS was defined from the time of diagnosis to the date of death or the date of the last follow-up.
Table 1. Patient characteristics.

|                                | Cohort 1 (n = 289) | Cohort 2 (n = 130) | p-value |
|--------------------------------|---------------------|---------------------|---------|
| Age at diagnosis, median (range) | 58 (18–73)          | 60 (18–74)          | 0.13    |
| Age at HCT decision, median (range) | 60 (18–74)          |                     |         |
| Age at HCT failure, median (range) | 67 (19–75)          |                     |         |
| Age at HCT, median (range) | 61 (18–75)          |                     |         |
| Days until HCT from diagnosis, median (range) | 280 (56–5453) |                     |         |
| Days until HCT from HCT decision, median (range) | 175 (41–1171) |                     |         |
| Males/females, n (% within cohort) | 168/124 (58%/42%)   | 82/48 > (63%/37%)   | 0.34    |
| Therapy related disease, <Q/In (% within cohort) | 43 (15%)           | 18 (14%)            | 0.78    |
| Diagnosed at University Hospital | 181 (63%)           |                     |         |
| Comorbidity index at HCT decision, median (range) | 70 (10–100)         | 70 (20–100)         | 0.85    |
| Marital status, n (%) | 2 (0–10)            |                     |         |
| Divorced | 17 (13%)           |                     |         |
| Married/partner | 85 (65%)          |                     |         |
| Single | 25 (19%)           |                     |         |
| Widow/widowed | 3 (2%)            |                     |         |
| Transfusion dependent (erythrocytes), n (% within cohort) | 143 (50%)          | 61 (47%)           | 0.61    |
| Cellularity %, median (range) | 70 (10–100)         | 70 (20–100)         | 0.85    |
| Marrow blast % (n = 281) | 0 (0–4)             | 103 (37%)           | 0.21    |
| 0.0–4.9 | 50 (36%)           |                     |         |
| 0.0–10.0 | 88 (31%)          | 44 (34%)           | 0.61    |
| 10.1–19.9 | 90 (32%)          | 30 (23%)           | 0.06    |
| ANC (10⁹/L) (n = 285) | ≥0.8 | 192 (67%)           | 95 (73%) | 0.24    |
| ≤0.7 | 93 (33%)           | 35 (27%)           |         |
| Platelets (10⁹/L) (n = 289) | ≥100 | 115 (40%)           | 67 (52%) | 0.67    |
| 50–99 | 97 (33%)           | 33 (25%)           | 0.09    |
| ≤49 | 77 (27%)           | 30 (23%)           | 0.44    |
| Hemoglobin (g/dL) | ≥10 | 133 (46%)           | 70 (53%) | 0.14    |
| 8.0–9.9 | 105 (36%)          | 51 (39%)           | 0.57    |
| ≤7.9 | 51 (18%)           | 9 (7%)            | 0.004   |
| WHO 2016 subgroups at diagnosis, n (% within cohort) | n = 280 |                     |         |
| Mixed MDS/MPN | 52 (18.6%)          | 19 (14.6%)         | 0.33    |
| IPSS-R risk group, n (% within cohort) | n = 265 | n = 126 |         |
| Very low | 5 (2%)             | 7 (6%)            | 0.05    |
| Low | 31 (12%)           | 19 (15%)           | 0.35    |
| Intermediate | 48 (18%)          | 42 (33%)          | 0.001   |
| High | 72 (27%)           | 27 (21%)           | 0.22    |
| Very high | 109 (41%)         | 31 (25%)          | 0.001   |
| IPSS-R prognostic subgroup (karyotype), n (% within cohort) | Very good | 1 (0.5%)         | 0.2     |
| Good | 104 (39%)          | 69 (55%)          | 0.004   |
| Intermediate | 57 (21.5%)        | 17 (13%)         | 0.06    |
| Poor | 39 (15%)           | 18 (14%)          | 0.91    |

Table 1. continued

|                                | Cohort 1 (n = 289) | Cohort 2 (n = 130) | p-value |
|--------------------------------|---------------------|---------------------|---------|
| Treatment, all given, n (% within cohort) | Very poor | 64 (24%)          | 20 (16%) | 0.06 |
| ICT only | 69 (33%)          | 15 (12%)          |         |
| Aza and ICT | 25 (19%)         |                     |         |
| Neither Aza/ICT | 21 (16%) |                     |         |

Abbreviations: HCT allogeneic hematopoietic stem cell transplantation, ANC absolute neutrophil count, Plt platelet count, Hb hemoglobin level, WHO World Health Organization, MDS/MPN myelodysplastic/myeloproliferative neoplasm unclassifiable, IPSS-R revised international prognostic score system, Aza azacytidine, ICT intensive chemotherapy.

RESULTS

Patient population

Cohort 1. The Swedish national MDS registry contained a total of 3607 patients with MDS or MDS/MPN whereof 1538 were aged 18–74 years. Seven cases did not cover information regarding HCT intent and were excluded. Patients were excluded if HCT was planned but not yet performed (n = 2) and if allocated to the group “transplantation might be performed” (n = 153). In total, we included 289 patients in cohort 1 (Fig. 1). The proportion of patients aged 18–74 being envisaged for HCT, excluding patients allocated to the group “transplantation might be performed”, was 19% (n = 291). The median age at diagnosis was 58 years (range 18–73), and 58% were male. Fifteen % and 19% were therapy-related diseases and mixed MDS/MPN, respectively. Most patients belonged to the IPSS-R risk groups intermediate, high, or very high. Compared to cohort 2, cohort 1 had fever patients with IPSS-R intermediate, high, or very high. A majority (63%) of the patients were diagnosed in a university hospital with a transplantation clinic.

Cohort 2. We identified 767 patients diagnosed with MDS or MDS/MPN at the Karolinska University Hospital, whereof 431 were aged between 18 and 74. The proportion of patients aged 18–74 being envisaged for HCT was 30% (n = 131) (Table 1 and Fig. 1). One patient was excluded since transplantation was pending but not yet performed and in total 130 patients were included in cohort 2. The median age at the decision to proceed to HCT was 60 y (range 18–74) and 63% were male. HCT was performed after a median of 175 days (range 41–171) after the documentation of the patient being an HCT candidate and 280 days (range 56–5453) after diagnosis. The median age at HCT or date when the patient was considered no longer eligible for HCT was 60 and 67 y, respectively. Most WHO 2016 classification groups were represented including 14% with therapy-related disease and 14% with mixed MDS/MPN. Most patients belonged to the IPSS-R risk groups intermediate, high, or very high. All IPSS-R karyotype risk

All statistical calculations were performed using SPSS version 25.0 (IBM, NY, United States).
Table 2. Univariate analysis of variables associated with failure to reach HCT.

| Variable                                                                 | Cohort 1 (n = 289) | Cohort 2 (n = 130) |
|--------------------------------------------------------------------------|-------------------|--------------------|
|                                                                           | No HCT (n = 72)   | HCT (n = 217)      | p-value | No HCT (n = 28) | HCT (n = 102) | p-value |
| Age at diagnosis, median (range)                                         | 61 (19–70)       | 57 (18–73)        | 0.006   | 65 (19–74)     | 59 (18–74)    | 0.01    |
| Age at HCT decision, median (range)                                      | 65 (19–4)        | 59 (18–73)        | 0.02    | 126 (11–1681)  | 105 (4–5309)  | 0.92    |
| Days until HCT decision from diagnosis, median (range)                   | 126 (11–1681)    | 105 (4–5309)      | 0.92    | 126 (11–1681)  | 105 (4–5309)  | 0.92    |
| Males, n (% of cohort)                                                   | 46 (27%)         | 122 (63%)         | 0.25    | 19 (23%)       | 63 (77%)      | 0.55    |
| Therapy-related disease, n (% of cohort)                                 | 15 (35%)         | 28 (65%)          | 0.10    | 6 (33%)        | 12 (67%)      | 0.19    |
| Diagnosed at University Hospital                                         | 49 (27%)         | 132 (73%)         | 0.27    | 49 (27%)       | 132 (73%)     | 0.27    |
| Comorbidity index, median (range), at HCT decision                       | 2 (0–10)         | 2 (0–6)           | 0.08    | 2 (0–10)       | 2 (0–6)       | 0.08    |
| Marital status, n (%)                                                    |                  |                   |         |                |                |         |
| Divorced                                                                 | 5 (29%)          | 12 (71%)          | 0.40    | 5 (29%)        | 12 (71%)      | 0.40    |
| Married/partner                                                         | 17 (20%)         | 68 (80%)          | 0.55    | 17 (20%)       | 68 (80%)      | 0.55    |
| Single                                                                   | 5 (20%)          | 20 (80%)          | 0.84    | 5 (20%)        | 20 (80%)      | 0.84    |
| Widow/widowed                                                           | 1 (33%)          | 2 (67%)           | 0.62    | 1 (33%)        | 2 (67%)       | 0.62    |
| No partner                                                              | 11 (24%)         | 35 (76%)          | 0.63    | 11 (24%)       | 35 (76%)      | 0.63    |
| Transfusion dependent (erythrocytes), n (% of cohort)                    | 42 (29%)         | 101 (69%)         | 0.09    | 14 (23%)       | 47 (77%)      | 0.71    |
| Cellularity %, median (range)                                            | 75 (10–100)      | 70 (10–100)       | 0.66    | 70 (40–100)    | 70 (20–100)   | 0.23    |
| Marrow blast %                                                           | n = 69a          | n = 212a          |         |                |                |         |
| 0–4.9                                                                   | 37 (36%)         | 66 (64%)          | 0.001   | 14 (25%)       | 24 (75%)      | 0.40    |
| 5.0–10.0                                                                | 20 (23%)         | 68 (77%)          | 0.63    | 7 (16%)        | 37 (84%)      | 0.26    |
| 10.1–19.9                                                               | 12 (13%)         | 78 (86%)          | 0.003   | 7 (23%)        | 23 (77%)      | 0.79    |
| ANC (10^9/L)                                                             | n = 72           | n = 217           |         |                |                |         |
| ≥0.8                                                                    | 51 (27%)         | 141 (73%)         | 0.47    | 22 (23%)       | 73 (77%)      | 0.46    |
| ≤0.7                                                                    | 21 (23%)         | 72 (77%)          | 0.47    | 6 (17%)        | 29 (83%)      | 0.46    |
| Platelets (10^9/L)                                                       | n = 72           | n = 217           |         |                |                |         |
| ≥100                                                                    | 27 (23%)         | 88 (77%)          | 0.65    | 17 (25%)       | 50 (75%)      | 0.27    |
| 50–99                                                                   | 23 (24%)         | 74 (76%)          | 0.74    | 5 (15%)        | 28 (85%)      | 0.30    |
| ≤49                                                                     | 22 (29%)         | 55 (71%)          | 0.39    | 6 (20%)        | 24 (80%)      | 0.82    |
| Hemoglobin (g/dL)                                                        | n = 72           | n = 217           |         |                |                |         |
| ≥10                                                                     | 24 (18%)         | 109 (82%)         | 0.01    | 13 (19%)       | 57 (81%)      | 0.37    |
| 8.0–9.9                                                                 | 31 (30%)         | 74 (70%)          | 0.17    | 11 (22%)       | 40 (78%)      | 0.99    |
| ≤7.9                                                                    | 17 (33%)         | 34 (67%)          | 0.13    | 4 (44%)        | 5 (56%)       | 0.08    |
| Mixed MDS/MPN                                                            | 19 (36%)         | 33 (64%)          | 0.03    | 6 (32%)        | 13 (68%)      | 0.25    |
| Variable                                                                 | Cohort 1, (n = 265) | Cohort 2, (n = 126) |
| IPSS-R risk group, n (%)                                                 | No HCT(1)        | HCT(1)            | p-value | No HCT(1)      | HCT(1)        | p-value |
| Very low                                                                 | 2 (40%)          | 3 (60%)           | 0.38    | 0              | 7 (100%)       | 0.16    |
| Low                                                                      | 12 (39%)         | 19 (61%)          | 0.03    | 4 (21%)        | 15 (79%)       | 0.97    |
| Intermediate                                                             | 7 (15%)          | 41 (85%)          | 0.11    | 9 (21%)        | 33 (79%)       | 0.99    |
| High                                                                     | 13 (18%)         | 59 (82%)          | 0.21    | 5 (18%)        | 22 (82%)       | 0.68    |
| Very high                                                                | 28 (26%)         | 81 (74%)          | 0.46    | 9 (29%)        | 22 (71%)       | 0.24    |
| Prognostic subgroup (karyotype), n (%)                                    |                  |                   |         |                |                |         |
| Very good                                                                | 0                | 1 (100%)          | 0.58    | 1 (50%)        | 1 (50%)        | 0.32    |
| Good                                                                     | 22 (21%)         | 82 (79%)          | 0.42    | 12 (17%)       | 57 (83%)       | 0.22    |
| Intermediate                                                             | 13 (23%)         | 44 (77%)          | 0.85    | 1 (6%)         | 16 (94%)       | 0.09    |
| Poor                                                                     | 7 (18%)          | 32 (82%)          | 0.36    | 7 (39%)        | 11 (61%)       | 0.05    |
| Very poor                                                                | 21 (33%)         | 43 (67%)          | 0.05    | 6 (30%)        | 14 (70%)       | 0.31    |
groups were represented. The median comorbidity score (HCT-CI) [19] was 2 (range 0–10), and 65% had a registered partner. A total of 109 (84%) of the patients received disease-modifying treatment (Aza or ICT) during the pre-HCT process, while 21 (16%) patients remained untreated.

Overlap between cohort 1 and 2
A proportion of the patients (n = 57) included in cohort 2 were correspondingly included in cohort 1. The remaining patients in cohort 2 (n = 73) were not included in cohort 1 due to (1) difference in time period (n = 25); (2) delay in reporting to the registry (n = 26); (3) HCT reported as “might be performed” in registry (n = 5) or reported as not planned for HCT (n = 17). Fourteen of the 17 patients reported as not planned for HCT were transplanted later than one year after diagnosis and most likely, these were not considered transplantation candidates upfront but later progressed and were then reevaluated. See supplementary figure S1 for details.

Characteristics of patients who fail to reach HCT
The number of patients who failed to reach HCT was 72/289 (25%) and 28/130 (22%) in cohort 1 and 2, respectively. The time between the date when the patient was identified as a potential HCT candidate and the date when the patient was considered ineligible for HCT (cohort 2 data only) was 153 days (range 11–430 days). Cause of failure to reach HCT (cohort 2 data only) were progressive/refractory disease (n = 13; 47%), no suitable donor identified (n = 6; 21%), identification of comorbidity (n = 5; 18%) and infection (n = 4; 14%), (Fig. 2). The patients with progression/refractory disease had all received cytoreductive treatment: Aza (n = 6, 2–9 cycles) ICT (n = 2, 1–2 cycles) or Aza + ICT (n = 5, Aza 3–8 cycles, ICT 1–2 cycles). Median percentage of blasts in the bone marrow in these patients were 15% (range 0.5–58%) at the time of decision to cancel the HCT. Two patients who had blast counts ≤5 were considered no longer HCT candidates due to (a) hemophagocytic lymphohistiocytosis driven by the MDS disease, and (b) IPSS-R very poor and a remaining large TP53 clone. No suitable donor could be identified upfront in four patients, and donor withdrawal was observed in two patients where no new donor could be identified. The cause of failure to reach HCT for the five patients with severe comorbidity was critical illness polyneuropathy (n = 1), severe fatigue (n = 2), depression (n = 1) and social insufficiency/alcohol-related disorder (n = 1). The infections resulting in failure to reach transplantation were all invasive fungal infections.

Factors associated with failure to reach HCT
Univariate analysis. Factors associated with higher failure rate in cohort 1 were age (61 y in the failure group vs 57 y in the HCT group; p = 0.006), mixed MDS/MPN (36% failure rate; p = 0.03), IPSS-R low (39%; p = 0.03), lower marrow blast count (0–4.9%, 36%; p = 0.001)) and IPSS-R karyotype "Very Poor" (33%; p = 0.05). Patients with higher marrow blast count had a lower failure rate (13%, p = 0.003). See Table 2 for details.

In cohort 2, factors associated with higher failure rate were age (65 vs 59 y; p = 0.01), IPSS-R karyotype "Poor" (39%; p = 0.05). The other factors associated with failure rate in cohort 1 could not be replicated in cohort 2. Data on pre-HCT treatment was only available for cohort 2. There was no significant difference in failure rate between patients treated with Aza or patients treated with ICT (22%, p = 0.95 and 28%, p = 0.27). Twenty-one patients were planned for HCT upfront without any disease-modifying treatment prior to HCT. Two of these did not get transplanted due to no identified donor.

Multivariate analysis. Multivariate analysis of failure rate was performed in both cohorts separately and included all variables with p-value ≤ 0.1 in the univariate analysis. In cohort 1, the included variables were: age at diagnosis, marrow blast category 0–4.9% and > 0%, hemoglobin level category ≥ 10 g/dL, WHO 2016 subgroup mixed MDS/MPN, therapy-related disease, and IPSS-R karyotype very-poor. Blast count 0–4.9%, very poor cytogenetics and age remained independently associated with failure to reach HCT (OR 2.59, p = 0.003, OR 2.0, p = 0.05 and OR 1.05, p = 0.003, respectively) while hemoglobin ≥ 10 g/dL at diagnosis were independently associated with a lower risk of failure (OR 0.45, p = 0.02). See Table 3 for details.

The included variables in cohort 2 were: age at diagnosis, comorbidity index, Hb ≤ 7.9, IPSS-R karyotype intermediate, and

---

### Table 2. continued

| Variable                  | Cohort 1 (n = 289) | p-value | Cohort 2 (n = 130) | p-value |
|---------------------------|--------------------|---------|--------------------|---------|
| All given treatment       |                    |         |                    |         |
| Aza only                  | 15 (22%)           |         | 54 (78%)           | 0.95    |
| ICT only                  | 4 (27%)            |         | 11 (73%)           | 0.60    |
| Aza and ICT               | 7 (28%)            |         | 18 (72%)           | 0.38    |
| Neither Aza/ICT           | 2 (10%)            |         | 19 (90%)           | 0.14    |

Abbreviations: HCT allogeneic hematopoietic stem cell transplantation, ANC absolute neutrophil count, Plt platelet count, Hb hemoglobin level, WHO World Health Organization, IPSS-R revised international prognostic score system, Aza azacytidine, ICT intensive chemotherapy.

*Data missing in 1 patient.

+ Data missing in 18 patients.

- Data missing in 43 patients.

% Data missing in 3 patients.

$ Data missing in 5 patients.

[ Data missing in 4 patients.

( Data missing in 2 patients.

( Data missing in 7 patients.

( Data missing in 3 patients.

+ Data missing in 1 patient.

+ Data missing in 13 patients.

+ Data missing in 4 patients.

+ Data missing in 2 patients.

+ Data missing in 7 patients.

+ Data missing in 3 patients.
poor. Only age was independently associated with a higher risk of failure (OR 1.05, \( p = 0.04 \)).

**Survival**

**Cohort 1.** After a median follow up from diagnosis of 29 (range 1–131) months, 129 patients were still alive. Estimated median OS was 44 months, with a longer median OS for transplanted patients vs patients who failed to reach HCT (83 vs 14 months; \( p < 0.001 \)). There was a survival benefit for transplanted patients in all IPSS-R risk groups except for IPSS-R very low and low where no significant difference was observed (Fig. 3). Moreover, there was a survival benefit for transplanted patients over failure patients also in the MDS/MPN risk group.

### Table 3. Multivariate analysis of variables associated with failure to reach HCT.

| Variable | Cohort 1 (\( n = 289 \)) | Cohort 2 (\( n = 130 \)) |
|----------|--------------------------|--------------------------|
|          | OR  | 95% CI | \( p\)-value | OR  | 95% CI | \( p\)-value |
| Age at diagnosis | 1.05 | 1.02–1.09 | 0.003 | 1.05 | 1.00–1.09 | 0.04 |
| Therapy-related disease | 1.74 | 0.79–3.87 | 0.17 | 1.2 | 0.98–1.53 | 0.07 |
| Comorbidity index | 2.59 | 1.39–4.82 | 0.003 | 0.50 | 0.21–1.19 | 0.12 |
| Marrow blast 0–4.9% | 0.45 | 0.24–0.87 | 0.02 | 2.9 | 0.62–12.8 | 0.18 |
| Marrow blast 10.1–19.9% | 0.65 | 0.37–1.13 | 0.12 | 0.40 | 0.17–0.92 | 0.04 |
| Hemoglobin ≥ 10 g/dL | 0.45 | 0.24–0.87 | 0.02 | 2.9 | 0.62–12.8 | 0.18 |
| WHO2016 Mixed MDS/MPN | 1.4 | 0.56–3.39 | 0.48 | 0.35 | 0.04–2.95 | 0.33 |
| IPSS-R prognostic subgroup (karyotype) intermediate | 0.35 | 0.04–2.95 | 0.33 | 2.44 | 0.80–7.43 | 0.12 |
| IPSS-R prognostic subgroup (karyotype) very poor | 2.0 | 1.01–4.12 | 0.05 |

Abbreviations: WHO World Health Organization, IPSS-R revised international prognostic score system.

**Fig. 2** Swimmer plot illustrating patients who fail to reach HCT (\( n = 28 \)), with the time of HCT decision as time zero. The triangle indicates the date when the patient no longer was considered eligible for HCT. The colors indicate reason for failure (yellow = identification of comorbidity, grey = infection, orange = no donor, blue = progress/refractory disease). Six patients were alive at date of last follow-up, indicated with an arrow. Abbreviations: HCT allogeneic hematopoietic stem cell transplantation.
After a median follow-up from diagnosis of 41.5 (range 3−235) months after HCT decision, 70 patients were still alive. Estimated median OS was 82 months, with a longer median OS for transplanted patients (105 vs 26 months; \( p < 0.001 \)). Twenty-seven patients (25%) relapsed after HCT after a median of 10 (range 3−56) months. Eighteen patients died due to non-relapse mortality after a median of four (range 2−51) months.

Six patients who failed to reach HCT were alive at end of observation. The cause of failure in these patients were lack of donor (\( n = 4 \)), progressive disease (\( n = 1 \)) and identification of...
comorbidity \((n = 1)\). The patient with progression had an observation time of three months after the decision to cancel the transplantation. The patient with comorbidity had developed severe depression. Twenty-two patients who failed to reach HCT were dead at the last follow-up, with a median time between the date when the patient was no longer considered a candidate for HCT and death of 1.4 months (0–36 months). Cause of death was disease progression \((n = 14, 64\%)\), infection \((n = 7, 32\%)\), and pulmonary embolism \((n = 1, 4\%)\), see Fig. 2.

DISCUSSION

The transplantation process for patients with MDS is a challenging task and includes both patient and donor-related issues: the disease needs to be under control, a donor needs to be identified and the patient should not acquire severe infections or co-morbidities during the pre-transplantation process. In addition, several logistical challenges must be overcome. The outcome for patients eligible for HCT is often presented as survival after HCT, but we know that a proportion of patients do not reach transplantation. Previous studies on the proportion of patients not being transplanted mainly consist of selected cohorts from single transplantation centers or prospective studies \([7, 13–15]\). This is to our knowledge the first study analyzing outcomes for patients planned for HCT in a population-based material. We report a large proportion of patients not reaching HCT which underlines the difficulties to take patients through the pre-transplantation process and the importance of careful surveillance during this process.

A limitation of this study is the inability to identify patients in cohort 1 who are recorded as non-HCT candidates in the registry due to low-risk disease, but then experience disease progression and are reconsidered as HCT candidates. Another obvious limitation of the data in cohort 1, is recall bias when doctors are reporting to the registry, where patients who might already have been transplanted upon registration are reported as “HCT planned” while failure patients might be recorded as “HCT not planned” despite an initial intent to transplant these patients. Since cohort 2 includes detailed data from patient charts, the limitations of cohort 1 described above do not exist for cohort 2.

The factors associated with failure to reach HCT can be divided into patient-related (e.g., age), disease-related (e.g., risk profile, hemoglobin level), donor-related (no donor identified or donor withdrawn). Potentially there are also physician-related factors and center bias factors. The intriguing finding that patients with blast count < 5% and patients with the lower-risk disease have a higher failure rate in cohort 1 might be attributed to a more passive pre-transplantation work-up and delayed HCT or due to less careful disease surveillance. This is obviously speculation, and other reasons for failure to reach HCT e.g., revised transplantation indication for patients admitted to transplantation centers from rural hospitals, revised transplantation indication due to sub-optimal donor or patient refusal, might be important. Interestingly, there was no significant difference in the failure rate for patients diagnosed in a rural hospital compared to patients diagnosed at a university hospital (27% vs 21%; \(p = 0.27\)) which would argue for a similar selection of transplantation candidates at Swedish rural hospitals compared to university hospitals.

The most frequent cause of failure to reach HCT in this cohort is progressive/refractory disease which is in line with the two recently published prospective studies \([14, 15]\). Our study underscores the importance of active treatment and disease surveillance for this group of patients. Potentially, newer treatments can reduce the number of patients who fail to reach HCT due to progressive/refractory disease.

A small number of patients failed to reach HCT due to a lack of donor. Due to the recent development of using haploidentical-donors, the number of patients not being possible to transplant because of lack of donor, could probably be decreased \([20]\).

We observed an OS benefit for transplanted patients in both cohorts. The difference in survival might partly be explained by patient selection, where patients who fail to reach HCT might be more fragile and/or have a more serious disease. Interestingly, the survival difference for patients with ipSS-R intermediate, where HCT is controversial, demonstrates a large survival benefit for patients being transplanted. Again, selection bias could contribute but the large difference between the groups might support HCT for these patients. Conversely, there is no survival benefit for patients with ipSS-R low and very low and a careful selection of patients who are candidates for HCT should be applied for these patients \([21]\).

In summary, we have in a population-based cohort shown that there is a significant proportion of patients failing to reach HCT underlining the difficulties to bring patients to HCT. New tools such as new treatments, new donor sources, and new surveillance methods can hopefully reduce the rate of patients failing to reach HCT.

REFERENCES

1. Hellström-Lindberg E, Tobissson M, Greenberg P. Myelodysplastic syndromes: moving towards personalized management. Haematologica. 2020;105:1765–79.
2. Myelodysplastic Syndrome (MDS)-Report from the National Quality Register for Diagnostic Year 2009-2017: RCC; 2018 [Available from: https://www.cancercentrum.se/sarverkan/cancerdiagnoser/blod-lymfom-myelom/myelodysplastiskt-syndrom-mds/kvalitetsregister/.
3. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017;129:1753–62.
4. Cazzola M. Myelodysplastic Syndromes. N. Engl J Med. 2020;383:1358–74.
5. Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkoza B, Myerson D et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood. 2012;120:1398–408.
6. Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukaemiaNet. Blood. 2013;122:2943–64.
7. Yahng SA, Kim M, Kim TM, Jeon YW, Yoon JH, Shin SH et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts. Oncotarget. 2017;8:12342–54.
8. Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E et al. Comparison between Upfront Transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2019;25:1550–9.
9. Rautenberg C, Germini U, Stepanow S, Lauseker M, Köhler K, Jäger PS et al. Influence of somatic mutations and pretransplant strategies in patients allo-grafted for myelodysplastic syndrome or secondary acute myeloid leukemia. Am J Hematol. 2021;96:E115–7.
10. Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129:2347–58.
11. Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohy M et al. Impact of azacitidine before allo genetic stem-cell transplantation for myelodysplastic syn dromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire et le Groupe-Francophone des Myelodysplasies. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:4533–40.
12. Damaj G, Mohy M, Robin M, Michallet M, Chevalier P, Beguin Y, et al. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2014;20:1349–55.
13. Getta BM, Kishitgari A, Hilden P, Tallman MS, Maloy M, Gonzales P et al. Allo geneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transpl. 2017;23:1074–86.
14. Kroeger N, Sockel K, Wolschke C, Behge W, Schlcn RF, Wolf D et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol. 2021;39:3318–27.
15. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328–39.

16. Moreno Berggren D, Folkvaljon Y, Engvall M, Sundberg J, Lambe M, Antunovic P, et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Br J Haematol. 2018;181:614–27.

17. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:391–405.

18. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

19. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

20. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, et al. Reduced-intensity allogeneic transplant for acute myeloid leukemia and myelodysplastic syndrome using combined CD34-selected haploidentical graft and a single umbilical cord unit compared with matched unrelated donor stem cells in older adults. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl. 2018;24:997–1004.

21. Robin M, Fenaux P. Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation? Leukemia 2020;34:2552–60.

ACKNOWLEDGEMENTS
The authors would like to thank regionalt Cancercentrum Örebro Uppsala for invaluable help with the data collection and express our gratitude to Professor Eva Hellström Lindberg for her valuable discussions.

AUTHOR CONTRIBUTIONS
CL, EO, and MT designed the study, collected data, and performed the statistical analyses. CL, EO, MC, LN, HG, JC, PL, EE, and MT analyzed the data and wrote the manuscript.

FUNDING
Open access funding provided by Karolinska Institute.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41409-022-01582-0.

Correspondence and requests for materials should be addressed to C. Lindholm.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022